{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:18:41Z","timestamp":1792603121103,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Given that mycosis fungoides\u2212cutaneous T-cell lymphoma (MF\/CTCL) is chronic, there is a need for additional therapies with minimal short- and long-term adverse effects. Topical synthetic hypericin ointment, 0.25%, activated with visible light is a novel, nonmutagenic photodynamic therapy (PDT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the efficacy and safety of topical synthetic hypericin ointment, 0.25%, activated with visible light as a nonmutagenic PDT in early-stage MF\/CTCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Settings, and Participants<\/jats:title>\n                    <jats:p>This was a multicenter, placebo-controlled, double-blinded, phase 3 randomized clinical trial (FLASH study) conducted from December 2015 to November 2020 at 39 academic and community-based US medical centers. Participants were adults (\u226518 years) with early-stage (IA-IIA) MF\/CTCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>In cycle 1, patients were randomized 2:1 to receive hypericin or placebo to 3 index lesions twice weekly for 6 weeks. In cycle 2, all patients received the active drug for 6 weeks to index lesions. In cycle 3 (optional), both index and additional lesions received active drug for 6 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end point was index lesion response rate (ILRR), defined as 50% or greater improvement in modified Composite Assessment of Index Lesion Severity (mCAILS) score from baseline after 6 weeks of therapy for cycle 1. For cycles 2 and 3, open label response rates were secondary end points. Adverse events (AEs) were assessed at each treatment visit, after each cycle, and then monthly for 6 months. Data analyses were performed on December 21, 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study population comprised 169 patients (mean [SD] age, 58.4 [16.0] years; 96 [57.8%] men; 120 [72.3%] White individuals) with early-stage MF\/CTCL. After 6 weeks of treatment, hypericin PDT was more effective than placebo (cycle 1 ILRR, 16% vs 4%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.04). The ILRR increased to 40% in patients who received 2 cycles of hypericin PDT (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u2009.001 vs cycle 1 hypericin) and to 49% after 3 cycles (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u2009.001 vs cycle 1 hypericin). Significant clinical responses were observed in both patch and plaque type lesions and were similar regardless of age, sex, race, stage IA vs IB, time since diagnosis, and number of prior therapies. The most common treatment-related AEs were mild local skin (13.5%-17.3% across cycles 1-3 vs 10.5% for placebo in cycle 1) and application-site reactions (3.2%-6.9% across cycles 1-3 vs 4% for placebo in cycle 1). No drug-related serious AEs occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance<\/jats:title>\n                    <jats:p>The findings of this randomized clinical trial indicate that synthetic hypericin PDT is effective in early-stage patch and plaque MF\/CTCL and has a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02448381\">NCT02448381<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.2749","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T11:02:30Z","timestamp":1658314950000},"page":"1031","source":"Crossref","is-referenced-by-count":56,"title":["Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)"],"prefix":"10.1001","volume":"158","author":[{"given":"Ellen J.","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Mangold","sequence":"additional","affiliation":[{"name":"Mayo Clinic Arizona, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"DeSimone","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer Institute, Annandale, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry K.","family":"Wong","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Seminario-Vidal","sequence":"additional","affiliation":[{"name":"USF Health Morsani Center for Advanced Health Care, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Guitart","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine at Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Appel","sequence":"additional","affiliation":[{"name":"PMG Research of Wilmington, Wilmington, North Carolina"},{"name":"Campbell University\u2212Sampson Regional Medical Center, Buies Creek, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Geskin","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lain","sequence":"additional","affiliation":[{"name":"Austin Institute for Clinical Research, Pflugerville, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Korman","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Zeitouni","sequence":"additional","affiliation":[{"name":"Medical Dermatology Specialists, University of Arizona, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Nikbakht","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Dawes","sequence":"additional","affiliation":[{"name":"Dawes Fretzin Dermatology Group, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Akilov","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joi","family":"Carter","sequence":"additional","affiliation":[{"name":"Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michi","family":"Shinohara","sequence":"additional","affiliation":[{"name":"University of Washington\u2212Seattle Cancer Care Alliance, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Kuzel","sequence":"additional","affiliation":[{"name":"Rush University Cancer Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Piette","sequence":"additional","affiliation":[{"name":"Rush University Cancer Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Therapeutics Clinical Research, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Musiek","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pariser","sequence":"additional","affiliation":[{"name":"Virginia Clinical Research, Norfolk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Elston","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Boh","sequence":"additional","affiliation":[{"name":"Tulane University, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"University of Texas\u2212MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auris","family":"Huen","sequence":"additional","affiliation":[{"name":"University of Texas\u2212MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Pacheco","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Zwerner","sequence":"additional","affiliation":[{"name":"Vanderbilt Dermatology, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Tae","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Maryland Comprehensive Cancer Center, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Girardi","sequence":"additional","affiliation":[{"name":"Yale New Haven Hospital, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[{"name":"City of Hope and Beckman Research Institute, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Bohjanen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Olsen","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Wood","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rumage","sequence":"additional","affiliation":[{"name":"Soligenix Inc, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreola","family":"Donini","sequence":"additional","affiliation":[{"name":"Soligenix Inc, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Haulenbeek","sequence":"additional","affiliation":[{"name":"Soligenix Inc, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Schaber","sequence":"additional","affiliation":[{"name":"Soligenix Inc, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Straube","sequence":"additional","affiliation":[{"name":"Soligenix Inc, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Pullion","sequence":"additional","affiliation":[{"name":"Soligenix Inc, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Rook","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Poligone","sequence":"additional","affiliation":[{"name":"Rochester Skin Lymphoma Medical Group, Fairport, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"18","key":"doi220034r1","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009.","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"doi220034r2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous T cell lymphoma.","volume":"7","author":"Dummer","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"doi220034r4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/php.1986.43.issue-6","article-title":"Hypericin and its photodynamic action.","volume":"43","author":"Dur\u00e1n","year":"1986","journal-title":"Photochem Photobiol"},{"issue":"2","key":"doi220034r5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2174\/1381612053382287","article-title":"Hypericin: the facts about a controversial agent.","volume":"11","author":"Kubin","year":"2005","journal-title":"Curr Pharm Des"},{"key":"doi220034r6","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3389\/fpls.2016.00560","article-title":"Hypericin in the Light and in the Dark: Two sides of the same coin.","volume":"7","author":"Jend\u017eelovsk\u00e1","year":"2016","journal-title":"Front Plant Sci"},{"issue":"5","key":"doi220034r7","first-page":"1343","article-title":"Selective enrichment of hypericin in malignant glioma: pioneering in vivo results.","volume":"38","author":"Noell","year":"2011","journal-title":"Int J Oncol"},{"issue":"4","key":"doi220034r8","first-page":"2579","article-title":"Photodynamic activity of hypericin in human urinary bladder carcinoma cells.","volume":"20","author":"Kamuhabwa","year":"2000","journal-title":"Anticancer Res"},{"issue":"5","key":"doi220034r9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1358\/dof.1995.020.05.305540","article-title":"Hypericin in adjuvant brain tumor therapy.","volume":"20","author":"Anker","year":"1995","journal-title":"Drugs Future"},{"issue":"4","key":"doi220034r10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/(ISSN)1097-0215","article-title":"Antimetastatic activity of the photodynamic agent hypericin in the dark.","volume":"111","author":"Blank","year":"2004","journal-title":"Int J Cancer"},{"issue":"4","key":"doi220034r11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1227\/00006123-199410000-00017","article-title":"Hypericin: a potential antiglioma therapy.","volume":"35","author":"Couldwell","year":"1994","journal-title":"Neurosurgery"},{"issue":"1","key":"doi220034r12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0304-3835(97)00287-5","article-title":"Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor.","volume":"120","author":"Zhang","year":"1997","journal-title":"Cancer Lett"},{"issue":"5","key":"doi220034r13","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/php.2009.85.issue-5","article-title":"Role of p38 MAPKs in hypericin photodynamic therapy-induced apoptosis of nasopharyngeal carcinoma cells.","volume":"85","author":"Chan","year":"2009","journal-title":"Photochem Photobiol"},{"issue":"5","key":"doi220034r14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1078\/0944-7113-00057","article-title":"Photodynamic therapy of murine fibrosarcoma with topical and systemic administration of hypericin.","volume":"8","author":"Cavarga","year":"2001","journal-title":"Phytomedicine"},{"issue":"3","key":"doi220034r15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11060-007-9514-0","article-title":"Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in a GH4C1 rat tumor model.","volume":"87","author":"Cole","year":"2008","journal-title":"J Neurooncol"},{"issue":"1","key":"doi220034r16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0304-3835(99)00381-X","article-title":"Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model.","volume":"150","author":"Chen","year":"2000","journal-title":"Cancer Lett"},{"issue":"5","key":"doi220034r17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1562\/0031-8655(2002)076<0509:ATEBHM>2.0.CO;2","article-title":"Antivascular tumor eradication by hypericin-mediated photodynamic therapy.","volume":"76","author":"Chen","year":"2002","journal-title":"Photochem Photobiol"},{"issue":"5","key":"doi220034r18","first-page":"1401","article-title":"Hypericin-mediated photodynamic therapy induces lipid peroxidation and necrosis in nasopharyngeal cancer.","volume":"23","author":"Du","year":"2003","journal-title":"Int J Oncol"},{"issue":"4","key":"doi220034r19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.pdpdt.2012.03.006","article-title":"Effects of hypericin and a chlorin based photosensitizer alone or in combination in squamous cell carcinoma cells in the dark.","volume":"9","author":"Besic Gyenge","year":"2012","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"4","key":"doi220034r20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pdpdt.2011.04.003","article-title":"Low dose hypericin-PDT induces complete tumor regression in BALB\/c mice bearing CT26 colon carcinoma.","volume":"8","author":"Sanovic","year":"2011","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"2","key":"doi220034r21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.1594","article-title":"Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: implication for whole bladder wall photodynamic therapy.","volume":"97","author":"Kamuhabwa","year":"2002","journal-title":"Int J Cancer"},{"issue":"10","key":"doi220034r22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8100093","article-title":"Hypericin in the dark: foe or ally in photodynamic therapy?","volume":"8","author":"Huntosova","year":"2016","journal-title":"Cancers (Basel)"},{"key":"doi220034r23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.tiv.2017.01.005","article-title":"Assessing light-independent effects of hypericin on cell viability, ultrastructure and metabolism in human glioma and endothelial cells.","volume":"40","author":"Huntosova","year":"2017","journal-title":"Toxicol In Vitro"},{"issue":"8","key":"doi220034r24","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/sj.bjc.6602512","article-title":"Elucidation of the tumoritropic principle of hypericin.","volume":"92","author":"Van de Putte","year":"2005","journal-title":"Br J Cancer"},{"issue":"1","key":"doi220034r25","first-page":"41","article-title":"Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring.","volume":"32","author":"Avci","year":"2013","journal-title":"Semin Cutan Med Surg"},{"issue":"2-3","key":"doi220034r26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1011-1344(96)07446-5","article-title":"Differential cytotoxic effects induced after photosensitization by hypericin.","volume":"38","author":"Vandenbogaerde","year":"1997","journal-title":"J Photochem Photobiol B"},{"issue":"1","key":"doi220034r27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1751-1097.1998.tb05174.x","article-title":"Cytotoxicity and antiproliferative effect of hypericin and derivatives after photosensitization.","volume":"67","author":"Vandenbogaerde","year":"1998","journal-title":"Photochem Photobiol"},{"issue":"3","key":"doi220034r28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1039\/C3PP50333J","article-title":"ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses.","volume":"13","author":"Garg","year":"2014","journal-title":"Photochem Photobiol Sci"},{"issue":"2","key":"doi220034r29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1523-1747.1998.00278.x","article-title":"Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders.","volume":"111","author":"Fox","year":"1998","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi220034r30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12977-019-0467-0","article-title":"Hypericin-photodynamic therapy inhibits the growth of adult T-cell leukemia cells through induction of apoptosis and suppression of viral transcription.","volume":"16","author":"Xu","year":"2019","journal-title":"Retrovirology"},{"issue":"6","key":"doi220034r31","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaad.2010.02.039","article-title":"A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.","volume":"63","author":"Rook","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi220034r32","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"issue":"20","key":"doi220034r33","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"18","key":"doi220034r34","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"doi220034r35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials.","volume":"35","author":"O\u2019Brien","year":"1979","journal-title":"Biometrics"},{"key":"doi220034r36","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.","author":"Olsen","year":"2021","journal-title":"Blood"},{"issue":"3","key":"doi220034r37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"issue":"5","key":"doi220034r38","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi220034r39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"doi220034r3","unstructured":"National Comprehensive Cancer Network. Cutaneous Lymphomas, version 2, 2022. Accessed June 22, 2022. https:\/\/www.nccn.org\/guidelines"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2794396\/jamadermatology_kim_2022_oi_220034_1662573740.39865.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T11:08:59Z","timestamp":1663758539000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2794396"}},"subtitle":["The FLASH Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.2749","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}